What the rules actually say.
Key FDA actions on research peptides: warning letters, compounding decisions, and committee votes. Each item links to the primary source.
Informational only. Not legal or medical advice. For guidance on your specific situation, consult a licensed attorney or clinician.
Where each peptide stands
Every peptide in the Merit Verified catalog, placed in its current FDA regulatory bucket. Tap any peptide to see its full evidence profile.
Full FDA approval for human use. Legal with a valid prescription.
In FDA-regulated clinical trials. Not yet approved for general use.
PCAC recommended 503A inclusion in July 2026. FDA has not added these to the bulks list yet. Still restricted until rulemaking finishes.
No FDA evaluation for compounding. Sold as research use only. Gray-market status.
Reviewed September 13, 2026 · Classifications sourced from FDA.gov. This page rebuilds nightly.
Status today
Most research peptides, including BPC-157, TB-500, and GHK-Cu, are not FDA-approved. They are not legal for human use outside a licensed compounding pharmacy or an investigational new drug (IND) program. Vendors often label products “research use only.” FDA has said that label is not a legal shield. In July 2026 the Pharmacy Compounding Advisory Committee recommended adding BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax to the 503A bulks list. That vote is advisory. FDA still has to finish rulemaking. A further PCAC meeting is expected before the end of February 2027 for GHK-Cu and several other compounds. Enforcement against gray-market storefronts continued in August 2026.
Last reviewed: September 13, 2026 · Informational only — not legal or medical advice.
Timeline
Reverse-chronological. Every item links to its primary source.
- Upcoming
PCAC expected to take up GHK-Cu, LL-37, Dihexa, PEG-MGF, and Melanotan II
A second Pharmacy Compounding Advisory Committee meeting is expected before the end of February 2027. The docket is expected to include GHK-Cu, Cathelicidin LL-37, Dihexa acetate, PEG-MGF, and Melanotan II. Until that meeting and any later FDA rulemaking, those compounds stay outside the 503A bulks list.
McDermott Will & Schulte - Enforcement
FDA sends another wave of warning letters to research-peptide storefronts
On August 24, 2026, FDA posted warning letters to several online peptide sellers, including Peptide Partners LLC, Royal Peptides LLC, Tex Peptides, and Peak Performance Peptides. The letters name unapproved GLP-1 products sold under coded labels, plus tesamorelin, PT-141, and SS-31. The agency treated the listings as unapproved new drugs, not as a research-use exception.
FDA.gov - Rulemaking
PCAC recommends BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax for the 503A list
On July 23–24, 2026, the Pharmacy Compounding Advisory Committee recommended adding BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax (free base and acetate) to the 503A bulks list. It voted against Emideltide (DSIP). The votes were close and ran against FDA staff’s recommendation not to include the substances. The recommendations are advisory. FDA still has to decide through notice-and-comment rulemaking, so the vote is not permission to compound today.
FDA.gov - Enforcement
FDA sends 30 additional warning letters and names BPC-157 with GLP-1s and SARMs
On March 3, 2026, FDA issued 30 more warning letters to telehealth and direct-to-consumer companies. The agency said it views “research use only” labeling as a ruse, not a legal shield, and named BPC-157 in the same enforcement context as compounded GLP-1 products and SARMs.
FDA.gov - Enforcement
FDA issues 50+ warning letters in a direct-to-consumer peptide crackdown
FDA sent more than 50 warning letters to companies marketing compounded peptides directly to consumers. The action targeted vendors and telehealth platforms selling BPC-157, TB-500, and related compounds outside the approved-drug framework.
FDA.gov - Rulemaking
FDA places about 19 peptides on the Category 2 significant-safety-concerns list
FDA moved approximately 19 peptides to a Category 2 designation, citing significant safety concerns including potential cancer, liver, kidney, and cardiovascular risks. Most popular research peptides, including BPC-157, were not FDA-approved for human use.
FDA.gov
Merit Verified publishes this tracker as a factual reference for researchers and buyers trying to understand the regulatory environment. It is not legal advice, medical advice, or a compliance guide. Rules and enforcement posture change — check primary sources for the most current information. The existing "research use only" disclaimer on Merit Verified applies in full to all content on this page.